On June 2, PegBio Pharma-B rose 10.55% in regular trading, trading at HK$8.75/share, with trading volume of HK$115 million.

On the news front, the company released multiple positive catalysts in quick succession. Its self-developed circular RNA-encoded GLP-1 analogue CR059 has been accepted by the 62nd European Association for the Study of Diabetes Annual Meeting (EASD 2026) and selected for the oral discussion session, following its earlier selection as a Late-Breaking Abstract at the ADA Annual Meeting. The consecutive recognition by two top-tier global diabetes conferences underscores the differentiated potential of CR059 as a next-generation ultra-long-acting metabolic disease therapy with monthly or even quarterly dosing intervals.

Meanwhile, the board proposed a general mandate to repurchase up to 10% of issued H shares, subject to shareholder approval at the June 24 annual general meeting. Additionally, the company's core commercial product Vepegnatide injection was included in the second batch of reference drug pre-communication supplementary disclosure, reinforcing medical insurance access expectations. The convergence of these catalysts drove the stock sharply higher.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)